Literature DB >> 20298968

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.

Zaven S Khachaturian1, Deborah Barnes, Richard Einstein, Sterling Johnson, Virginia Lee, Allen Roses, Mark A Sager, William R Shankle, Peter J Snyder, Ronald C Petersen, Gerard Schellenberg, John Trojanowski, Paul Aisen, Marilyn S Albert, John C S Breitner, Neil Buckholtz, Maria Carrillo, Steven Ferris, Barry D Greenberg, Michael Grundman, Ara S Khachaturian, Lewis H Kuller, Oscar L Lopez, Paul Maruff, Richard C Mohs, Marcelle Morrison-Bogorad, Creighton Phelps, Eric Reiman, Marwan Sabbagh, Mary Sano, Lon S Schneider, Eric Siemers, Pierre Tariot, Jacques Touchon, Bruno Vellas, Lisa J Bain.   

Abstract

Among the major impediments to the design of clinical trials for the prevention of Alzheimer's disease (AD), the most critical is the lack of validated biomarkers, assessment tools, and algorithms that would facilitate identification of asymptomatic individuals with elevated risk who might be recruited as study volunteers. Thus, the Leon Thal Symposium 2009 (LTS'09), on October 27-28, 2009 in Las Vegas, Nevada, was convened to explore strategies to surmount the barriers in designing a multisite, comparative study to evaluate and validate various approaches for detecting and selecting asymptomatic people at risk for cognitive disorders/dementia. The deliberations of LTS'09 included presentations and reviews of different approaches (algorithms, biomarkers, or measures) for identifying asymptomatic individuals at elevated risk for AD who would be candidates for longitudinal or prevention studies. The key nested recommendations of LTS'09 included: (1) establishment of a National Database for Longitudinal Studies as a shared research core resource; (2) launch of a large collaborative study that will compare multiple screening approaches and biomarkers to determine the best method for identifying asymptomatic people at risk for AD; (3) initiation of a Global Database that extends the concept of the National Database for Longitudinal Studies for longitudinal studies beyond the United States; and (4) development of an educational campaign that will address public misconceptions about AD and promote healthy brain aging. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298968      PMCID: PMC4298995          DOI: 10.1016/j.jalz.2010.01.008

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  19 in total

1.  Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.

Authors:  Mark A Sager; Bruce Hermann; Asenath La Rue
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

2.  Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors.

Authors:  Peter J Snyder; Kathryn V Papp; Jennifer Bartkowiak; Colleen E Jackson; Rachelle S Doody
Journal:  Alzheimers Dement       Date:  2009-03       Impact factor: 21.566

3.  Creating a transatlantic research enterprise for preventing Alzheimer's disease.

Authors:  Zaven S Khachaturian; Jordi Camí; Sandrine Andrieu; Jesús Avila; Mercè Boada Rovira; Monique Breteler; Lutz Froelich; Serge Gauthier; Teresa Gómez-Isla; Ara S Khachaturian; Lewis H Kuller; Eric B Larson; Oscar L Lopez; José Manuel Martinez-Lage; Ronald C Petersen; Gerard D Schellenberg; Jordi Sunyer; Bruno Vellas; Lisa J Bain
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

4.  The Nevada Vital Aging Initiative: a private-public partnership to study early predictors of dementia.

Authors:  Leon Thal; Lewis Kuller; Keith Bowman; John Breitner; Denis Evans; Lindsey Farrer; Richard Frank; Ara S Khachaturian; Zaven S Khachaturian; Walter Kukull; Javier Nieto; Ronald Petersen; Mark Sager; Paul Scherr; Lisa J Bain
Journal:  Alzheimers Dement       Date:  2007-01       Impact factor: 21.566

5.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

6.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

Authors:  M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  Predicting risk of dementia in older adults: The late-life dementia risk index.

Authors:  D E Barnes; K E Covinsky; R A Whitmer; L H Kuller; O L Lopez; K Yaffe
Journal:  Neurology       Date:  2009-05-13       Impact factor: 9.910

Review 9.  Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions.

Authors:  Kathryn V Papp; Stephen J Walsh; Peter J Snyder
Journal:  Alzheimers Dement       Date:  2009-01       Impact factor: 21.566

10.  Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease.

Authors:  L Mosconi; R Mistur; R Switalski; M Brys; L Glodzik; K Rich; E Pirraglia; W Tsui; S De Santi; M J de Leon
Journal:  Neurology       Date:  2008-11-12       Impact factor: 9.910

View more
  13 in total

Review 1.  Structural imaging in early pre-states of dementia.

Authors:  Charles D Smith
Journal:  Biochim Biophys Acta       Date:  2011-07-14

2.  Community engagement in diverse populations for Alzheimer disease prevention trials.

Authors:  Heather R Romero; Kathleen A Welsh-Bohmer; Lisa P Gwyther; Henry L Edmonds; Brenda L Plassman; Cassandra M Germain; Michelle McCart; Kathleen M Hayden; Carl Pieper; Allen D Roses
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jul-Sep       Impact factor: 2.703

Review 3.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Was phenserine a failure or were investigators mislead by methods?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2012-12       Impact factor: 3.498

5.  A Late Life Risk Index for Severe Cognitive Impairment in Mexico.

Authors:  Brian Downer; Sreenivas P Veeranki; Rebeca Wong
Journal:  J Alzheimers Dis       Date:  2016-03-08       Impact factor: 4.472

6.  Pre-clinical cognitive phenotypes for Alzheimer disease: a latent profile approach.

Authors:  Kathleen M Hayden; Maragatha Kuchibhatla; Heather R Romero; Brenda L Plassman; James R Burke; Jeffrey N Browndyke; Kathleen A Welsh-Bohmer
Journal:  Am J Geriatr Psychiatry       Date:  2013-09-27       Impact factor: 4.105

7.  Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit.

Authors:  Mary D Naylor; Jason H Karlawish; Steven E Arnold; Ara S Khachaturian; Zaven S Khachaturian; Virginia M-Y Lee; Matthew Baumgart; Sube Banerjee; Cornelia Beck; Kaj Blennow; Ron Brookmeyer; Kurt R Brunden; Kathleen C Buckwalter; Meryl Comer; Kenneth Covinsky; Lynn Friss Feinberg; Giovanni Frisoni; Colin Green; Renato Maia Guimaraes; Lisa P Gwyther; Franz F Hefti; Michael Hutton; Claudia Kawas; David M Kent; Lewis Kuller; Kenneth M Langa; Robert W Mahley; Katie Maslow; Colin L Masters; Diane E Meier; Peter J Neumann; Steven M Paul; Ronald C Petersen; Mark A Sager; Mary Sano; Dale Schenk; Holly Soares; Reisa A Sperling; Sidney M Stahl; Vivianna van Deerlin; Yaakov Stern; David Weir; David A Wolk; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2012-09       Impact factor: 21.566

8.  Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials.

Authors:  Joshua D Grill; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2010-12-21       Impact factor: 6.982

9.  Alzheimer Disease Worries, Fears, and Stigma and Their Relationship to Genetic and Interventional Research Engagement.

Authors:  Shoshana H Bardach; Saida Kent; Gregory A Jicha
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

10.  Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities.

Authors:  Francesca Pistollato; Elan L Ohayon; Ann Lam; Gillian R Langley; Thomas J Novak; David Pamies; George Perry; Eugenia Trushina; Robin S B Williams; Alex E Roher; Thomas Hartung; Stevan Harnad; Neal Barnard; Martha Clare Morris; Mei-Chun Lai; Ryan Merkley; P Charukeshi Chandrasekera
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.